Top 5 Healthcare Technology Stocks To Invest In 2014

“As U.S. politicians of both political parties are still shuffling back and forth between the White House and the Capitol Hill without striking a viable deal to bring normality to the body politic they brag about, it is perhaps a good time for the befuddled world to start considering building a de-Americanized world,” writes Liu Chang in Xinhua, China’s official news outlet. But can China build a de-Americanized world? Can China lead the global economy?

As we wrote in previous pieces, the answer is most likely not, as China lacks four conditions that make its economic growth sustainable.

First, China doesn’t have an “infinite” world market frontier for its manufacturing products, as its genuine expansion to world markets comes at a time when capitalism is already approaching its last frontier, having conquered almost every market around the world.

This means that China is pushing against capitalism’s last frontier, and, therefore, it has little room to maneuver before clashing with other world market players that are already well positioned in the global market.

Top 5 Healthcare Technology Stocks To Invest In 2014: BP Prudhoe Bay Royalty Trust (BPT)

BP Prudhoe Bay Royalty Trust operates as a grantor trust in the United States. The company holds overriding royalty interests constituting a non-operational interest in minerals in the Prudhoe Bay oil field located on the North Slope in Alaska. The Prudhoe Bay field extends approximately 12 miles by 27 miles and contains approximately 150,000 gross productive acres. As of December 31, 2012, its estimated net remaining proved reserves were 75.517 million barrels of oil and condensate, of which 70.676 million barrels are proved developed reserves and 4.841 million barrels are proved undeveloped reserves. The company was founded in 1989 and is based in Austin, Texas.

Advisors’ Opinion:

  • [By Rick Munarriz]

    BP Prudhoe Bay Royalty Trust (NYSE: BPT  ) is also fueling its distributions. The trust’s new quarterly payout comes out to $2.4147517 a unit. We’re really splitting pennies here, but it’s actually a reasonable 4% increase over its earlier rate.

  • [By Matt DiLallo]

    BP Prudhoe Bay Royalty Trust (NYSE: BPT  )
    Created in 1989, the property of the BP Prudhoe Bay Royalty Trust consists of an overriding royalty interest of oil and condensate production from BP’s Prudhoe Bay oil field located on the North Slope in Alaska. The trust makes quarterly payments to investors of the income after expenses, which can vary each quarter. Over the past year the trust has paid out an average of $2.22 per quarter which would imply a yield of around 9.4%. The key point that investors must understand is that the oil in the field is a finite resource, meaning that it will run out. Under current projections it’s expected that the trust will run dry around the year 2029.

Top 5 Healthcare Technology Stocks To Invest In 2014: Tetraphase Pharmaceuticals Inc (TTPH)

Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company’s product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company are developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. The Company’s frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. In 2012, in vitro experiments, eravacycline has demonstrated the ability to cover a variety of multi-drug resistant Gram-negative, Gram-positive, anaerobic and atypical bacteria, including multi-drug resistant Klebsiella pneumoniae, the species of Gram-negative bacteria that killed seven patients at the Clinical Center of the National Institutes of Health.

Gram-positive bacteria that have developed resistance to existing drugs include: Streptococcus pneumoniae that cause pneumonia, ear infections, bloodstream infections and meningitis; Staphylococcus aureus that cause skin, bone, lung and bloodstream infections, and Enterococci that are responsible for infections transmitted in healthcare settings. Gram-negative bacteria that have developed resistance to existing drugs include: Escherichia coli that cause urinary tract, skin and bloodstream infections; Salmonella and Escherichia coli that cause foodborne infections, and Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp.

In addition, other a ntibiotics that have been used as first-line empiric monothe! rapies, such as Levaquin, piperacillin/tazobactam, which is marketed by Pfizer as Zosyn, carbapenems, such as Merrem, and imipenem/cilastatin, which is marketed by Merck as Primaxin, have seen their utility as first-line empiric monotherapies diminished as the number of bacterial strains resistant to these therapies has increased. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. A number of previous tetracyclines have been available in both intravenous and oral dosage forms. Infections that are resistant to existing oral drugs are increasingly common, and the Company believe that an intravenous-to-oral step-down therapy in which patients are started on the intravenous formulation of eravacycline and then stepped down to an oral formulation of eravacycline could reduce the length of a patient’s hospital stay or help avoid hospital admission altogether, lowering the overall cost of care for these patien ts.

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another under-$10 biopharmaceutical player that’s starting to trend within range of triggering a near-term breakout trade is Tetraphase Pharmaceuticals (TTPH), which using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. This stock is off to a strong start in 2013, with shares up 19.4%.

    If you take a look at the chart for Tetraphase Pharmaceuticals, you’ll notice that this stock has just started to trend back above its 50-day moving average of $7.76 a share with decent upside volume flows. That move is quickly pushing shares of TTPH within range of breaking out above some key near-term overhead resistance levels that have acted as a ceiling for the stock for the last three months.

    Market players should now look for long-biased trades in TTPH if it manages to break out above some near-term overhead resistance levels at $8.30 to $8.40 a share and then once it takes out more resistance at $8.50 to $9 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 62,234 shares. If that breakout triggers soon, then TTPH will set up to re-test or possibly take out its all-time high at $9.66 a share. Any high-volume move above that level will then push TTPH into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $12 to $13 a share.

    Traders can look to buy TTPH off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $7.76 a share, or below more key near-term support levels at $7.37 to $7.02 a share. One can also buy TTPH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 5 Healthcare Technology Stocks To Invest In 2014: MicroChannel Technologies Corp (MCTC)

MicroChannel Technologies Corporation, incorporated on February 28, 2005, is a development-stage company. The Company is focused on the identification, acquisition, and development of new and potentially commercial opportunities.

As of August 31, 2013, the Company is not engaged in any business operations. As of August 31, 2013, the Company had no revenues.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap stocks Bonamour Inc (OTCBB: BONI), Firstin Wireless Technology Inc (OTCMKTS: FINW) and Microchannel Technologies Corp (OTCBB: MCTC) have been attracting attention from variosu investment newsletters lately with at least two of these stocks being the subject of paid promotions. Of course, there is nothing wrong with properly disclosed paid promotions or investor relation types of activities as its up to investors and traders alike to do their due diligence. So how hot are these small cap stocks? Here is a quick reality check that might cool your appetite:

Top 5 Healthcare Technology Stocks To Invest In 2014: Inc.(STMP) Inc. provides Internet-based postage solutions. The company offers solutions to mail and ship various mail pieces, including postcards, envelopes, flats, and packages. Its products and services include the United States Postal Service (USPS)-approved PC Postage Service that enables users to print electronic stamps directly onto envelopes, plain paper, or labels using personal computer, printer, and Internet connection; and PhotoStamps, a patented form of postage, which allows consumers to turn digital photos, designs, or images into valid United States postage. The company also sells NetStamps labels, shipping labels, other mailing labels, postage printers, scales, and other mailing and shipping-focused office supplies through its mailing and shipping supplies store, as well as offers back-end integration solutions, an electronic postage for transactions to manage the front-end process. In addition, it offers branded insurance enabling users to insure their mail or packages; and official USPS package insurance. Inc. serves individuals, small businesses, home offices, medium-size businesses, and large enterprises. The company was formerly known as StampMaster, Inc. and changed its name to Inc. in December 1998. Inc. was founded in 1996 and is headquartered in Los Angeles, California.

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Then there is that lucky or unlucky outcome of price hikes. The public will pay more for stamps, making you and me the losers in this. The question to ask is whether or not Inc. (NASDAQ: STMP) just get a built-in revenue booster per customer on a static basis?

  • [By Bryan Murphy]

    By almost any measure, Inc. (NASDAQ:STMP) is a solid investment. Revenue and profits are on the rise, and are projected to grow again in 2014. has also developed a penchant for earnings beats. And, at a trailing P/E of 18.3 and a forward-looking P/E ratio of 15.7, it’s not like STMP shares cost a relative fortune. Yet, STMP is starting to look like a major liability where it could hurt shareholders the most… on the chart.

  • [By Brian Pacampara]

    What: Shares of online postage provider (NASDAQ: STMP  ) surged 24% today after its quarterly results and guidance.

    So what: The stock has slumped a bit in 2013 on concerns over slowing growth, but today’s first-quarter results — adjusted EPS spiked 38% on a 13.5% revenue increase — and upbeat full-year guidance naturally eases some of those worries. In fact, hit its highest level of total paid customers — and added its largest number of new paid customers — during the quarter, giving investors plenty of good vibes about the company’s prospects going forward.

Top 5 Healthcare Technology Stocks To Invest In 2014: Spectra Energy Partners LP(SEP)

Spectra Energy Partners, LP operates as an investment arm of Spectra Energy Corp. Spectra Energy Partners, LP, through its subsidiaries, engages in the transportation of natural gas through interstate pipeline systems, and the storage of natural gas in underground facilities in the United States. As of December 31, 2007, it owned and operated 100% of the approximately 1,400-mile East Tennessee interstate natural gas transportation system that extends from central Tennessee eastward into southwest Virginia and northern North Carolina, and southward into northern Georgia; and a liquefied natural gas storage facility in Kingsport, Tennessee with working gas storage capacity of approximately 1.1 billion cubic feet (Bcf) and re-gasification capability of 150 million cubic feet per day. The company also owned a 24.5% interest in the approximate 700-mile Gulfstream interstate natural gas transportation system, which extends from Pascagoula, Mississippi, and Mobile, Alabama across the Gulf of Mexico and into Florida; a 50% interest in Market Hub, which owns and operates 2 salt cavern natural gas storage facilities, the Egan storage facility with gas capacity of approximately 20 Bcf, and the Moss Bluff storage facility with working gas capacity of 15 Bcf. The company transports and stores natural gas for local gas distribution companies, municipal utilities, interstate and intrastate pipelines, direct industrial users, electric power generators, marketers, and producers. Spectra Energy Partners (DE) GP, LP, operates as the general partner to Spectra Energy Partners, LP. The company is based in Houston, Texas.

Advisors’ Opinion:

  • [By Marc Bastow]

    Natural gas pipeline supplier Spectra Energy Partners (SEP) raised its quarterly dividend 5.8% to 54.625 cents per share, payable on Feb. 28 to shareholders of record as of Feb. 14.
    SEP Dividend Yield: 4.87%

  • [By Jon C. Ogg]

    Spectra Energy Corp. (NYSE: SE) was reiterated as Buy with a $38 price target (versus a $34.92 closing price) at Argus. The move follows the Spectra’s announcement that it will drop its storage and transmission assets down to its master limited partnership, Spectra Energy Partners L.P. (NYSE: SEP). Argus now believes that Spectra will be able to grow its dividend faster than the firm had originally projected and will be rewarded with a higher valuation multiple.

  • [By Jonas Elmerraji]

    Gas pipeline company Spectra Energy Partners (SEP) is showing traders the exact same setup right now — albeit slightly more textbook than Barrick’s. Spectra is another ascending triangle with resistance at $46. A breakout above the $46 level is the signal that it’s time to be a buyer in this nat gas transporter.

    Whenever you’re looking at any technical price pattern, it’s critical to think in terms of those buyers and sellers. Triangles and other pattern names are a good quick way to explain what’s going on in a stock, but they’re not the reason it’s tradable. Instead, it all comes down to supply and demand for shares.

    That $46 resistance level is a price where there has been an excess of supply of shares; in other words, it’s a place where sellers have been more eager to step in and take gains than buyers have been to buy. That’s what makes a breakout above it so significant — the move means that buyers are finally strong enough to absorb all of the excess supply above that price level.

    Don’t be early on this trade.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Spectra Energy Partners (NYSE: SEP  ) , whose recent revenue and earnings are plotted below.